SHINE Medical Technologies announced today that is has entered into a strategic agreement with the largest Chinese producer and distributor of radio-pharmaceuticals, HTA, to help with the supply of molybdenum (moly-99).

“HTA has a bold vision to grow nuclear medicine for the benefit of Chinese patients,” SHINE CEO Greg Piefer said in a statement. “I am thrilled that SHINE, one of the most exciting companies in nuclear medicine, is teaming up with HTA to ensure the largest growth market in the world is well supplied with these lifesaving products.”

According to a release, SHINE will provide the moly-99 for use in HTA’s technetium generators once SHINE’s facility in Janesville, Wis., becomes operational.

Financial terms of the agreement were not disclosed.